A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.
bicalutamide
flutamide
long-term
prostate cancer
Journal
Nagoya journal of medical science
ISSN: 2186-3326
Titre abrégé: Nagoya J Med Sci
Pays: Japan
ID NLM: 0412011
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
entrez:
19
12
2019
pubmed:
19
12
2019
medline:
6
5
2020
Statut:
ppublish
Résumé
Currently, the early introduction of new antiandrogens is popular for castration-resistant prostate cancer (CRPC). However, adverse events can be severe and their costs are high. Here, we present a patient with CRPC in whom flutamide controlled disease progression for 10 years. This case report shows that conventional alternative antiandrogens are cost effective and are still an important option for the treatment for CRPC.
Identifiants
pubmed: 31849389
doi: 10.18999/nagjms.81.4.707
pmc: PMC6892669
doi:
Substances chimiques
Anilides
0
Nitriles
0
Tosyl Compounds
0
Flutamide
76W6J0943E
bicalutamide
A0Z3NAU9DP
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
707-710Déclaration de conflit d'intérêts
The authors have nothing to disclose.
Références
Br J Urol. 1981 Apr;53(2):152-3
pubmed: 7237048
Jpn J Clin Oncol. 2014 Mar;44(3):263-9
pubmed: 24516203
Cancer Res. 2003 Jan 1;63(1):149-53
pubmed: 12517791
J Urol. 1997 Jul;158(1):160-3
pubmed: 9186345
J Urol. 1995 Aug;154(2 Pt 1):448-53
pubmed: 7541862
Biomed Res Int. 2016;2016:4083183
pubmed: 27493956
J Urol. 2008 Sep;180(3):921-7
pubmed: 18635218